These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 15056083)

  • 21. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment with chimeric monoclonal antitumor necrosis factor (infliximab) of patients with active steroid-dependent/resistant Crohn's disease and fistulas].
    Martorana G; Casà A; Oliva L; Orlando A; Cottone M
    Recenti Prog Med; 2001; 92(7-8):451-5. PubMed ID: 11475786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study.
    Orlando A; Colombo E; Kohn A; Biancone L; Rizzello F; Viscido A; Sostegni R; Benazzato L; Castiglione F; Papi C; Meucci G; Riegler G; Mocciaro F; Cassinotti A; Cosintino R; Geremia A; Morselli C; Angelucci E; Lavagna A; Rispo A; Bossa F; Scimeca D; Cottone M;
    Dig Liver Dis; 2005 Aug; 37(8):577-83. PubMed ID: 15886081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report.
    van der Hagen SJ; Baeten CG; Soeters PB; Russel MG; Beets-Tan RG; van Gemert WG
    Dis Colon Rectum; 2005 Apr; 48(4):758-67. PubMed ID: 15750797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of refractory fistulizing pouchitis with infliximab.
    Viscido A; Kohn A; Papi C; Caprilli R
    Eur Rev Med Pharmacol Sci; 2004; 8(5):239-46. PubMed ID: 15638238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infliximab therapy in Crohn's disease: a pragmatic approach?
    Kevans D; Keegan D; Mulcahy HE; O'Donoghue DP
    Aliment Pharmacol Ther; 2006 Jul; 24(2):351-9. PubMed ID: 16842462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab use in luminal Crohn's disease.
    Richter JA; Bickston SJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of response to infliximab in patients with fistulizing Crohn's disease.
    Luna-Chadid M; Pérez Calle JL; Mendoza JL; Vera MI; Bermejo AF; Sánchez F; López San Román A; Froilán C; González-Lara V; García-Paredes J; Fernández-Blanco I; Abreu L; Casis B; Solís Herruzo JA; Gisbert JP; Maté Jiménez J
    Rev Esp Enferm Dig; 2004 Jun; 96(6):379-81; 382-4. PubMed ID: 15230667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcome of Crohn's disease treated with infliximab.
    Arslan S; Kav T; Besisik F; Kaymakoglu S; Pinarbasi B; Tözün N; Hamzaoglu HO; Duman D; Ulker A; Parlak E; Palabiyikoglu M; Dökmeci A
    Hepatogastroenterology; 2003; 50(52):952-6. PubMed ID: 12845957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review article: Medical therapy for fistulizing Crohn's disease.
    Bressler B; Sands BE
    Aliment Pharmacol Ther; 2006 Nov; 24(9):1283-93. PubMed ID: 17059510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey.
    Matsumoto T; Iida M; Motoya S; Haruma K; Suzuki Y; Kobayashi K; Ito H; Miyata M; Kusunoki M; Chiba T; Yamamoto S; Hibi T
    Dis Colon Rectum; 2008 Jun; 51(6):916-23. PubMed ID: 18322754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infliximab maintenance therapy for fistulizing Crohn's disease.
    Sands BE; Anderson FH; Bernstein CN; Chey WY; Feagan BG; Fedorak RN; Kamm MA; Korzenik JR; Lashner BA; Onken JE; Rachmilewitz D; Rutgeerts P; Wild G; Wolf DC; Marsters PA; Travers SB; Blank MA; van Deventer SJ
    N Engl J Med; 2004 Feb; 350(9):876-85. PubMed ID: 14985485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Infliximab therapy in children and adolescents with refractory Crohn's disease in the Netherlands; experience with 23 patients].
    de Ridder L; Escher JC; Taminiau JA
    Ned Tijdschr Geneeskd; 2002 Oct; 146(40):1879-83. PubMed ID: 12395595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
    Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G
    Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guidelines for treatment with infliximab for Crohn's disease.
    Hommes DW; Oldenburg B; van Bodegraven AA; van Hogezand RA; de Jong DJ; Romberg-Camps MJ; van der Woude J; Dijkstra G;
    Neth J Med; 2006; 64(7):219-29. PubMed ID: 16929083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA; Villela R; Silverberg MS; Greenberg GR
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience.
    Topstad DR; Panaccione R; Heine JA; Johnson DR; MacLean AR; Buie WD
    Dis Colon Rectum; 2003 May; 46(5):577-83. PubMed ID: 12792431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined modality treatment for complex fistulating perianal Crohn's disease.
    Antakia R; Shorthouse AJ; Robinson K; Lobo AJ
    Colorectal Dis; 2013 Feb; 15(2):210-6. PubMed ID: 22672653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The prolonged administration of intravenous immunoglobulins as a treatment for refractory fistulous Crohn's diseases].
    González-Lara V; Carneros JA; Núñez-Martínez O; Rodríguez C; Escudero M; Alvarez R
    Gastroenterol Hepatol; 2000 Jan; 23(1):12-3. PubMed ID: 10726377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infliximab in fistulizing Crohn's disease.
    Osterman MT; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Dec; 35(4):795-820. PubMed ID: 17129814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.